Trial reportBMC anesthesiology2026
A novel dexmedetomidine nasal spray for gastrointestinal recovery in pediatric laparoscopic hernia repair: a randomized controlled trial.
Trial report in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePreoperative anxiety is common in pediatric surgical patients and may delay postoperative recovery. Conventional intranasal or nebulized dexmedetomidine often requires off-label dilution and manual assembly, which can lead to dosing inconsistency and variable mucosal absorption. We evaluated a novel dexmedetomidine nasal spray in children undergoing laparoscopic inguinal hernia repair.
methodsIn this study, 100 children aged 2–6 years scheduled for laparoscopic high ligation of the hernia sac for indirect inguinal hernia received either dexmedetomidine spray (Group D, n = 50) or saline (Group C, n = 50) 30 min before anesthesia. Primary outcome was time to first flatus; secondary outcomes included time to first defecation, time to tolerated oral intake, I-FEED scores on postoperative days 1–3, preoperative anxiety in children and parents, postoperative pain, and behavioral changes.
resultsGroup D showed significantly shorter time to first flatus (14.61 ± 4.19 h vs. 17.57 ± 5.96 h, P = 0.006), defecation (23.94 ± 7.22 h vs. 29.70 ± 7.63 h, P < 0.001) and time to tolerated oral intake (12.82 ± 5.94 h vs. 14.92 ± 7.02 h, P = 0.047). FLACC scores and I-FEED scores were also lower on day 1 (P = 0.015, P = 0.022, respectively). Intranasal dexmedetomidine attenuates preoperative anxiety in both children and parents and facilitates smoother separation from parents. No significant differences were found in behavioral changes. No serious adverse events occurred in the PACU.
conclusionA novel dexmedetomidine nasal spray improved gastrointestinal recovery and reduced preoperative anxiety and early postoperative pain without compromising safety, suggesting a practical and reproducible sedation strategy for pediatric perioperative care.
trial registrationChiCTR2400088326 Date: August 15, 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.